Your Cart Is Empty!
The following complimentary webcasts are scheduled. Please register to participate:
Please be aware that webinars are hosted through GoToWebinar. If you are not already set up to view webinars through this service, please allow 5 minutes before the start to establish access.
Tissue-based immunohistochemical (IHC) data are important and variability in staining quality has a major impact on data quality. Sometimes this is the only type of data available to support critical decisions in research, business, or diagnostics. Although that should be reason enough to care a great deal about data quality, often this seems to be an area with room for improvement. In a case study BRAF V600E (Run 37) with the Canadian Immunohistochemistry Quality Control (cIQc), participating laboratories were asked to stain a colorectal carcinoma tissue microarray enriched for MLH1-deficient cases. Additionally, the slides stained by the participating laboratories also contained BRAF V600E genetically defined IHC Reference Standard cell lines provided by Horizon Diagnostics. Image analysis was used to quantify the staining quality and compared to the assessor panel, with excellent results. Using the same analysis algorithms it was possible to reproduce the same correlation to the assessor panel, demonstrating the possibility of using genetically defined cell lines with automated image analysis to assess laboratory staining quality.
In this webinar we will focus on next generation sequencing and discuss: the effect of formalin treatment on molecular protocols and how it can be controlled, how to select the sequencing platform most appropriate for your sample, evaluation of whether structural variants are being detected by your assay and how Reference Standards can be used in each validation parameter.
The world of biomarker research has changed dramatically over the last 20 years with targeted therapy fundamentally changing drug development practices; there are not only new biomarkers but there are also complex biomarkers such as PD-L1. The situation has moved to a matrix of therapeutics and companion diagnostics, rather than the direct 1:1 relationship of the past. With all this complexity it is essential to ensure the accuracy of biomarker analysis, however, manual assessments of complex biomarker expressions have been associated with significant inter- and intra-reader variability. There are ways of reducing certain types of errors associated with biomarker assessment and studies have shown that quantitative image analysis may be the solution. Therefore an essential part of blue sky thinking is toward the development of HDx IHC Reference Standards and Quantitative Digital Pathology methods to deliver a strong scoring confidence.
Send us a message
See our ordering page
Click here to register with us
Find out here